sb 216763 has been researched along with Astrocytoma, Grade IV in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dong, Z; Du, S; Huang, J; Lei, T; Sun, M; Tong, R; Wang, H; Wang, Y; Yang, J; Yang, Y | 1 |
| Katz, SC; Sampath, P; Sengupta, S | 1 |
2 other study(ies) available for sb 216763 and Astrocytoma, Grade IV
| Article | Year |
|---|---|
Nuclear GSK3β induces DNA double-strand break repair by phosphorylating 53BP1 in glioblastoma.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; DNA Breaks, Double-Stranded; DNA Repair; Glioblastoma; Glycogen Synthase Kinase 3 beta; Humans; Indoles; Male; Maleimides; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphorylation; Protein Transport; Radiation, Ionizing; Serine; Survival Rate; Tumor Suppressor p53-Binding Protein 1; Xenograft Model Antitumor Assays | 2018 |
Glycogen synthase kinase 3 inhibition lowers PD-1 expression, promotes long-term survival and memory generation in antigen-specific CAR-T cells.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Combined Modality Therapy; Glioblastoma; Glycogen Synthase Kinase 3; Humans; Immunotherapy, Adoptive; Indoles; Lymphocyte Activation; Male; Maleimides; Mice; Receptors, Chimeric Antigen; T-Lymphocytes; Treatment Outcome; Xenograft Model Antitumor Assays | 2018 |